Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23641189 | 0.83 | ALDH1A1 (0.47) | ALDH1A1CNR2BCL2A1HTTRAB9A | |
| SCHEMBL27861501 | 0.74 | PHGDH (0.33) | ALDH1A1ALDH2MGLLHTTLMNA | |
| SCHEMBL25555106 | 0.71 | ALDH1A1 (0.73) | ALDH1A1ALDH2CNR2MGLLHTT | |
| SCHEMBL13064495 | 0.70 | ALDH1A1 (0.50) | ALDH1A1ALDH2CNR2HTTRAB9A | |
| SCHEMBL25969225 | 0.70 | ALDH1A1 (0.50) | ALDH1A1BCL2A1MGLLHTTRAB9A | |
| SCHEMBL8867879 | 0.69 | ALDH1A1 (0.49) | ALDH1A1ALDH2CNR2HTTRAB9A | |
| SCHEMBL25554741 | 0.67 | ALDH1A1 (0.65) | ALDH1A1ALDH2CNR2MGLLHTT | |
| SCHEMBL95412 | 0.67 | HDAC1 (0.52) | ALDH1A1ALDH2CNR2LMNA | |
| SCHEMBL9824179 | 0.66 | ALDH1A1 (0.49) | ALDH1A1CNR2HTTRAB9ACCR1 | |
| SCHEMBL27304840 | 0.66 | L3MBTL1 (0.44) | ALDH1A1ALDH2CNR2MGLLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SHH, GLI1, SMO | ALDH1A1 786/4885ALDH2 269/4885CNR2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.